DPP-1 Inhibitors Aim to Reduce Bronchiectasis Flare-Ups
A new class of drugs offers a disease-based approach to managing non-cystic fibrosis bronchiectasis by targeting airway inflammation.
A new class of drugs offers a disease-based approach to managing non-cystic fibrosis bronchiectasis by targeting airway inflammation.
Mechanical ventilation is one of the most common ICU interventions, and understanding and accurately interpreting ventilator graphics may reduce risks and improve patient outcomes.
Dynarex Corp launched a new Resp-O₂ Portable Oxygen Concentrator and a new line of infant- and pediatric-sized closed suction catheters.
ENA Respiratory received notices of allowance for two US patents covering its innate immune modulators and their application in preventing COPD exacerbations.